A next-generation Vertex Pharmaceuticals pain drug failed to beat a placebo in a Phase 2 clinical trial. Despite the disappointing outcome in bunionectomy pain, the company is continuing development of the oral drug in diabetic peripheral neuropathy. The post Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study appeared first on…
A small number of innovative health systems and plans have incorporated technology and cultural integrations that recognize the comprehensive cognitive, social, and environmental drivers and barriers that influence member behaviors. However, progress has been slow — here are three key areas where behavioral science can significantly impact plans and their members. The post Why Behavioral…
NEMT providers play a key role, providing lifelines by delivering the crucial connection between patients and the care they need. This responsibility becomes even more critical when serving individuals with special needs, such as those with physical disabilities, behavioral health conditions, developmental delays or age-related limitations. The post Its Own Reward: NEMT Services Meet Challenge…
Healthcare AI progress could soon stall due to fragmented, inaccessible data systems, warned OMNY Health CEO Mitesh Rao. He said that scalable AI requires a more interoperable data infrastructure — and without it, even it will be difficult for advanced AI solutions to succeed. The post Healthcare’s Poor Data Infrastructure Is Hindering AI Innovation in…
With HealthTap’s new direct virtual primary care program, members get ongoing access to a primary care doctor of their choosing through video visits and messaging. The post HealthTap Introduces Direct Virtual Primary Care Program appeared first on MedCity News.
Hansa Biopharma has encouraging early clinical results showing its drug imlifidase, used as a pretreatment, enabled Duchenne muscular dystrophy patients to receive the gene therapy Elevidys. Sarepta is searching for ways to mitigate excessive immune responses to Elevidys that can lead to serious and potentially fatal liver injury. The post Sarepta’s Future in Gene Therapy…
Prioritizing risk-based management, data science, smart automation, standards, and patient optionality are critical for the industry to keep up with market changes. The recent FDA guidance that encourages ‘pragmatic trials’ in specific scenarios is a move in the right direction. The post Carving a Path Toward Pragmatic Innovation in Clinical Trials appeared first on MedCity…
Today, people living with diabetes have several ways of monitoring glucose levels, whether through finger pricks or CGMs. Both ways of measuring glucose levels have benefits and limitations. The post The Future of Glucose Monitoring: Why Blood-Based Measurements Matter appeared first on MedCity News.
In a new analysis, the American Medical Association detailed the lack of competition among pharmacy benefit managers and their high level of vertical integration with insurers. The post New AMA Report Highlights Lack of Competition in PBM Market appeared first on MedCity News.
In a new action plan, the White House aims to boost the country’s AI innovation through deregulation, infrastructure expansion and new incentives. Overall, the move is welcomed by healthcare AI leaders — but they did notice some omissions, including AI safety, patient consent and the role of key healthcare regulators. The post What Do Digital…